BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kimman ML, Wijsenbeek MS, van Kuijk SMJ, Wijnsma KL, van de Kar NCAJ, Storm M, van Jaarsveld X, Dirksen CD; PESaM Collaborating Group. Validity of the Patient Experiences and Satisfaction with Medications (PESaM) Questionnaire. Patient 2019;12:149-62. [PMID: 30367435 DOI: 10.1007/s40271-018-0340-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
Number Citing Articles
1 James KA, Cadel L, Hitzig SL, Guilcher SJ. Patient-reported outcomes for medication-related quality of life: A scoping review. Research in Social and Administrative Pharmacy 2022. [DOI: 10.1016/j.sapharm.2022.03.003] [Reference Citation Analysis]
2 Aronson KI, Suzuki A. Health Related Quality of Life in Interstitial Lung Disease: Can We Use the Same Concepts Around the World? Front Med (Lausanne) 2021;8:745908. [PMID: 34692737 DOI: 10.3389/fmed.2021.745908] [Reference Citation Analysis]
3 Kalluri M, Luppi F, Ferrara G. What Patients With Idiopathic Pulmonary Fibrosis and Caregivers Want: Filling the Gaps With Patient Reported Outcomes and Experience Measures. Am J Med 2020;133:281-9. [PMID: 31520625 DOI: 10.1016/j.amjmed.2019.08.032] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 4.3] [Reference Citation Analysis]
4 Aronson KI, Danoff SK, Russell AM, Ryerson CJ, Suzuki A, Wijsenbeek MS, Bajwah S, Bianchi P, Corte TJ, Lee JS, Lindell KO, Maher T, Martinez FJ, Meek PM, Raghu G, Rouland G, Rudell R, Safford MM, Sheth JS, Swigris JJ. Patient-centered Outcomes Research in Interstitial Lung Disease: An Official American Thoracic Society Research Statement. Am J Respir Crit Care Med 2021;204:e3-e23. [PMID: 34283696 DOI: 10.1164/rccm.202105-1193ST] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5 Soto-Vidal C, Pacheco-da-Costa S, Calvo-Fuente V, Fernández-Guinea S, González-Alted C, Gallego-Izquierdo T. Validation of the Spanish Version of Newcastle Stroke-Specific Quality of Life Measure (NEWSQOL). Int J Environ Res Public Health 2020;17:E4237. [PMID: 32545844 DOI: 10.3390/ijerph17124237] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
6 Moor CC, Mostard RLM, Grutters JC, Bresser P, Aerts JGJV, Dirksen CD, Kimman ML, Wijsenbeek MS. Patient expectations, experiences and satisfaction with nintedanib and pirfenidone in idiopathic pulmonary fibrosis: a quantitative study. Respir Res 2020;21:196. [PMID: 32703201 DOI: 10.1186/s12931-020-01458-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 2.5] [Reference Citation Analysis]
7 Hillman LA, Peden-McAlpine C, Ramalho-de-Oliveira D, Schommer JC. The Medication Experience: A Concept Analysis. Pharmacy (Basel) 2020;9:7. [PMID: 33396387 DOI: 10.3390/pharmacy9010007] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
8 Cox IA, Borchers Arriagada N, de Graaff B, Corte TJ, Glaspole I, Lartey S, Walters EH, Palmer AJ. Health-related quality of life of patients with idiopathic pulmonary fibrosis: a systematic review and meta-analysis. Eur Respir Rev 2020;29:200154. [PMID: 33153990 DOI: 10.1183/16000617.0154-2020] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
9 Moor CC, Mostard RLM, Grutters JC, Bresser P, Aerts JGJV, Chavannes NH, Wijsenbeek MS. Home Monitoring in Patients with Idiopathic Pulmonary Fibrosis. A Randomized Controlled Trial. Am J Respir Crit Care Med 2020;202:393-401. [DOI: 10.1164/rccm.202002-0328oc] [Cited by in Crossref: 28] [Cited by in F6Publishing: 13] [Article Influence: 14.0] [Reference Citation Analysis]